DE69535562D1 - Rekombinantpeptide hergeleitet vom mc3 antikörper gegen ba46, verfahren zu deren verwendung und verfahren zur humanisierung von antikörperpeptiden - Google Patents

Rekombinantpeptide hergeleitet vom mc3 antikörper gegen ba46, verfahren zu deren verwendung und verfahren zur humanisierung von antikörperpeptiden

Info

Publication number
DE69535562D1
DE69535562D1 DE69535562T DE69535562T DE69535562D1 DE 69535562 D1 DE69535562 D1 DE 69535562D1 DE 69535562 T DE69535562 T DE 69535562T DE 69535562 T DE69535562 T DE 69535562T DE 69535562 D1 DE69535562 D1 DE 69535562D1
Authority
DE
Germany
Prior art keywords
peptides
antibodies
antibody
methods
humanization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69535562T
Other languages
English (en)
Other versions
DE69535562T2 (de
Inventor
Couto Fernando J Do
Roberto I Ceriani
Jerry A Peterson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CANCER RESEARCH INSTITUTE OF CONTRA COSTA, NEW, US
Original Assignee
Cancer Research Fund of Contra Costa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Fund of Contra Costa filed Critical Cancer Research Fund of Contra Costa
Application granted granted Critical
Publication of DE69535562D1 publication Critical patent/DE69535562D1/de
Publication of DE69535562T2 publication Critical patent/DE69535562T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69535562T 1994-09-16 1995-09-14 Rekombinantpeptide hergeleitet vom mc3 antikörper gegen ba46, verfahren zu deren verwendung und verfahren zur humanisierung von antikörperpeptiden Expired - Fee Related DE69535562T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30786894A 1994-09-16 1994-09-16
US307868 1994-09-16
US48759895A 1995-06-07 1995-06-07
US487598 1995-06-07
PCT/US1995/011683 WO1996008565A2 (en) 1994-09-16 1995-09-14 RECOMBINANT PEPTIDES DERIVED FROM THE Mc3 ANTI-BA46 ANTIBODY, METHODS OF USE THEREOF, AND METHODS OF HUMANIZING ANTIBODY PEPTIDES

Publications (2)

Publication Number Publication Date
DE69535562D1 true DE69535562D1 (de) 2007-09-27
DE69535562T2 DE69535562T2 (de) 2008-06-26

Family

ID=26975968

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69535562T Expired - Fee Related DE69535562T2 (de) 1994-09-16 1995-09-14 Rekombinantpeptide hergeleitet vom mc3 antikörper gegen ba46, verfahren zu deren verwendung und verfahren zur humanisierung von antikörperpeptiden

Country Status (10)

Country Link
US (1) US20090010848A1 (de)
EP (1) EP0784684B8 (de)
AT (1) ATE370235T1 (de)
AU (1) AU707159B2 (de)
CA (1) CA2200097A1 (de)
DE (1) DE69535562T2 (de)
DK (1) DK0784684T3 (de)
ES (1) ES2293642T3 (de)
PT (1) PT784684E (de)
WO (1) WO1996008565A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
CU23097A1 (es) * 2002-10-23 2005-11-18 Centro Inmunologia Molecular Método para la obtención de líneas celulares en medio libre de proteína y líneas celulares obtenidas por este método
BRPI0506726B8 (pt) * 2004-01-07 2021-05-25 Chiron Corp anticorpo monoclonal específico para m-csf e usos deste
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
PL2182983T3 (pl) 2007-07-27 2014-10-31 Janssen Alzheimer Immunotherap Leczenie chorób amyloidowych z wykorzystaniem humanizowanych przeciwciał specyficznych względem Abeta
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
WO2013139956A1 (en) * 2012-03-22 2013-09-26 Thrombogenics Nv Antibodies abrogating cell binding to lactadherin
US20180036442A1 (en) 2014-07-29 2018-02-08 Vrije Universiteit Brussel Radio-labelled antibody fragments for use in the prognosis, diagnosis of cancer as well as for the prediction of cancer therapy response
DK3174559T3 (da) * 2014-07-29 2022-12-05 Univ Brussel Vrije Radiomærkede antistoffragmenter til anvendelse inden for forebyggelsen og/eller behandlingen af cancer
US11298433B2 (en) 2015-07-17 2022-04-12 Vrije Universiteit Brussel Radiolabelled antibody fragments for use in treating cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9120467D0 (en) * 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
DE69332930T2 (de) * 1992-11-16 2004-02-26 Cancer Research Fund Of Contra Costa, Walnut Creek Peptide mit breiter neoplastischer spezifizität

Also Published As

Publication number Publication date
DK0784684T3 (da) 2007-12-17
CA2200097A1 (en) 1996-03-21
US20090010848A1 (en) 2009-01-08
WO1996008565A3 (en) 1996-07-11
WO1996008565A2 (en) 1996-03-21
ATE370235T1 (de) 2007-09-15
EP0784684B8 (de) 2008-03-26
PT784684E (pt) 2007-11-23
DE69535562T2 (de) 2008-06-26
AU3588795A (en) 1996-03-29
ES2293642T3 (es) 2008-03-16
EP0784684B1 (de) 2007-08-15
AU707159B2 (en) 1999-07-01
EP0784684A2 (de) 1997-07-23

Similar Documents

Publication Publication Date Title
DE69535562D1 (de) Rekombinantpeptide hergeleitet vom mc3 antikörper gegen ba46, verfahren zu deren verwendung und verfahren zur humanisierung von antikörperpeptiden
ATE137534T1 (de) Cdr-gepfropfte anti-cea-antikörper und ihre herstellung
ATE236251T1 (de) Anti-menschliche milchfettglobule humanisierte antikörper und verfahren zu ihrer herstellung
EA200301098A1 (ru) Ассоциированные с ганглиозидами рекомбинантные антитела и их применение в диагностике и лечении опухолей
EP1362868A3 (de) Humanisierte und chimäre monoklonale Antikörper die den Rezeptor für epidermalen Wachstumfaktor (EGF-R) binden
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
NZ303375A (en) Monoclonal antibodies specific for different epitopes of human gp39 and diagnostic and therapeutic methods using them
FI981799A (fi) DNA-molekyylejä, jotka koodaavat CD25 sitovia molekyylejä
HK1070907A1 (en) Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same
ATE148168T1 (de) Monoklonale antikörper
RU2380377C2 (ru) Nogo-A-СВЯЗЫВАЮЩИЕ МОЛЕКУЛЫ И ИХ ФАРМАЦЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: CANCER RESEARCH INSTITUTE OF CONTRA COSTA, NEW, US

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee